These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 25772338

  • 1. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S, Nikas SP, Shukla VG, Vemuri K, Makriyannis A, Järbe TU.
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [Abstract] [Full Text] [Related]

  • 2. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
    Lichtman AH, Fisher J, Martin BR.
    Pharmacol Biochem Behav; 2001 Aug; 69(1-2):181-8. PubMed ID: 11420084
    [Abstract] [Full Text] [Related]

  • 3. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR, Koek W.
    Eur J Pharmacol; 2007 Aug 13; 569(1-2):70-6. PubMed ID: 17553486
    [Abstract] [Full Text] [Related]

  • 4. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE.
    Drug Alcohol Depend; 2018 Nov 01; 192():285-293. PubMed ID: 30300803
    [Abstract] [Full Text] [Related]

  • 5. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
    Järbe TU, LeMay BJ, Vemuri VK, Vadivel SK, Zvonok A, Makriyannis A.
    Psychopharmacology (Berl); 2011 Aug 01; 216(3):355-65. PubMed ID: 21369753
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.
    Grim TW, Samano KL, Ignatowska-Jankowska B, Tao Q, Sim-Selly LJ, Selley DE, Wise LE, Poklis A, Lichtman AH.
    J Basic Clin Physiol Pharmacol; 2016 May 01; 27(3):217-28. PubMed ID: 27149200
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential disruption of response alternation by precipitated Δ9-THC withdrawal and subsequent Δ9-THC abstinence in mice.
    Eckard ML, Kinsey SG.
    Pharmacol Biochem Behav; 2024 Mar 01; 236():173718. PubMed ID: 38272272
    [Abstract] [Full Text] [Related]

  • 11. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
    Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, Selley DE, Lichtman AH, Sim-Selley LJ.
    Neuropsychopharmacology; 2010 Jul 01; 35(8):1775-87. PubMed ID: 20357755
    [Abstract] [Full Text] [Related]

  • 12. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW, Redhi GH, Vemuri K, Makriyannis A, Le Foll B, Bergman J, Goldberg SR, Justinova Z.
    Neuropsychopharmacology; 2016 Aug 01; 41(9):2283-93. PubMed ID: 26888056
    [Abstract] [Full Text] [Related]

  • 13. Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.
    Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH.
    J Pharmacol Exp Ther; 2017 Jul 01; 362(1):210-218. PubMed ID: 28442584
    [Abstract] [Full Text] [Related]

  • 14. AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice.
    Järbe TU, Tai S, LeMay BJ, Nikas SP, Shukla VG, Zvonok A, Makriyannis A.
    Psychopharmacology (Berl); 2012 Mar 01; 220(2):417-26. PubMed ID: 21989802
    [Abstract] [Full Text] [Related]

  • 15. Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice.
    Vanegas SO, Reck AM, Rodriguez CE, Marusich JA, Yassin O, Sotzing G, Wiley JL, Kinsey SG.
    Drug Alcohol Depend; 2022 Nov 01; 240():109640. PubMed ID: 36179506
    [Abstract] [Full Text] [Related]

  • 16. Diuretic effects of cannabinoids.
    Paronis CA, Thakur GA, Bajaj S, Nikas SP, Vemuri VK, Makriyannis A, Bergman J.
    J Pharmacol Exp Ther; 2013 Jan 01; 344(1):8-14. PubMed ID: 23019138
    [Abstract] [Full Text] [Related]

  • 17. Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210.
    Serrano A, Vadas E, Ferrer B, Bilbao A, Granado N, Suárez J, Pavon FJ, Moratalla R, Rodríguez de Fonseca F.
    Psychopharmacology (Berl); 2021 Feb 01; 238(2):551-557. PubMed ID: 33410990
    [Abstract] [Full Text] [Related]

  • 18. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
    Trexler KR, Nass SR, Crowe MS, Gross JD, Jones MS, McKitrick AW, Siderovski DP, Kinsey SG.
    Drug Alcohol Depend; 2018 Oct 01; 191():14-24. PubMed ID: 30071445
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
    DeLong GT, Wolf CE, Poklis A, Lichtman AH.
    Drug Alcohol Depend; 2010 Nov 01; 112(1-2):126-33. PubMed ID: 20619971
    [Abstract] [Full Text] [Related]

  • 20. CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.
    Trexler KR, Eckard ML, Kinsey SG.
    Pharmacol Biochem Behav; 2019 Feb 01; 177():27-33. PubMed ID: 30597181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.